Mesoblast hosts expert webinar on Ryoncil as first line after steroids
Mesoblast Limited (ASX:MSB; Nasdaq:MESO) hosted a key opinion leader webinar this week highlighting the use of Ryoncil as first line after steroids for pediatric acute graft versus host disease. The session was titled “The Graft-versus-Host Disease Exchange – Expert Perspectives on Evolving Clinical Practice.”
The speaker was Dr. Susan Prockop, Associate Professor, Harvard Medical School, and Attending Physician & Director, Boston Children’s Hospital. The company described her as a leading pediatric transplant and cellular-therapy specialist.
Dr. Prockop provided an overview of Ryoncil (remestemcel-L-rknd) as a new treatment paradigm in the management of acute graft-versus-host disease. She also covered its use as first line after steroids, highlighted case studies, and discussed results from pivotal trials.
For investors, the session puts an independent Harvard-affiliated specialist on record discussing Ryoncil’s use earlier in the treatment pathway. A replay of the webcast is available via the link labelled “GvHD Exchange Nov2026”.
When big ASX news breaks, our subscribers know first
What Ryoncil is and why the treatment setting matters
Acute graft-versus-host disease (GvHD) is a condition in which donor cells attack the patient’s tissue after a transplant. Steroids are commonly the initial treatment.
“Steroid-refractory” describes patients who do not respond to steroids. This is the setting in which Ryoncil is approved.
Ryoncil is indicated for steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older. According to Mesoblast, it is the first FDA-approved mesenchymal stromal cell (MSC) therapy.
The webinar’s discussion of use as first line after steroids points to how clinicians are considering Ryoncil’s role in practice. Mesoblast states Ryoncil is also being developed for additional inflammatory diseases, including:
Data from the expanded access programme show Ryoncil delivering consistently high survival rates across patient subgroups, which frames how clinicians weigh its use earlier in the treatment pathway.
- SR-aGvHD in adults
- Biologic-resistant inflammatory bowel disease
Mesoblast’s platform, IP and commercial footprint
Mesoblast describes itself as a world leader in developing allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. Key elements of its profile include:
- An allogeneic (off-the-shelf) cellular medicines platform
- Over 1,000 granted patents or patent applications, providing commercial protection extending through to at least 2044 in all major markets
- Commercial partnerships established in Japan, Europe and China
Beyond Ryoncil, the company states rexlemestrocel-L is being developed for heart failure and chronic low back pain. Mesoblast has locations in Australia, the United States and Singapore, and is listed on the Australian Securities Exchange (MSB) and the Nasdaq (MESO).
Ryoncil’s first full commercial year lifted FY2026 revenue to US$120.25M from US$17.2M, funding the adult trial and late-stage pipeline.
| Fact | Impact |
|---|---|
| Ryoncil is the first FDA-approved MSC therapy for pediatric SR-aGvHD in patients 2 months and older | Establishes the approved setting discussed in the webinar |
| Over 1,000 granted patents or patent applications | Commercial protection extending through to at least 2044 in all major markets |
| Commercial partnerships established in Japan, Europe and China | Extends the company’s commercial reach beyond its own locations |
Don’t Miss the Next Healthcare Breakout
Join 20,000+ investors receiving FREE breaking ASX news within minutes of release, complete with in-depth analysis already done. Click the “Free Alerts” button at Big News Blast to get healthcare and other market-moving announcements in your inbox the moment they break, ahead of the wider market.